Ticker

6/recent/ticker-posts

Header Ads Widget

‘Watson’ with Morris Chestnut Earns a Season 2 Order

Watson Star Morris Chestnut
Watson Star Morris Chestnut
Morris Chestnut stars in ‘Watson’ (Photo: Colin Bentley © 2024 CBS Broadcasting, Inc)

Watson starring Morris Chestnut has officially been renewed by CBS for a second season. The network has now confirmed the status of most of its scripted 2024-2025 primetime lineup, with FBI: International, FBI: Most Wanted, and SWAT ending after their current seasons. The Equalizer is one of the few shows left to learn its fate.

The series premiere has been seen by 18.7 million viewers and, according to CBS, is the most-streamed episode of all the network’s original series this season. Season one has been averaging 6.79 million viewers.

Season one stars Morris Chestnut as Dr. John Watson, Eve Harlow as Ingrid Derian, Peter Mark Kendall as Dr. Stephens Croft and Dr. Adam Croft, and Ritchie Coster as Shinwell Johnson. Inga Schlingmann is Sasha Lubbock and Rochelle Aytes stars as Dr. Mary Morstan.

Watson takes place six months after the death of the titular character’s friend and partner Sherlock Holmes at the hands of Moriarty. The show stars Morris Chestnut as Dr. John Watson who resumes his medical career as the head of a clinic dedicated to treating rare disorders. Watson’s old life isn’t done with him, though—Moriarty and Watson are set to write their own chapter of a story that has fascinated audiences for more than a century,” reads CBS’s synopsis. “Watson is a medical show with a strong investigative spine, featuring a modern version of one of history’s greatest detectives as he turns his attention from solving crimes to solving medical mysteries.

Craig Sweeny serves as showrunner and executive producer. Morris Chestnut, Sallie Patrick, Larry Teng, Shäron Moalem MD, PhD, Kapital Entertainment’s Aaron Kaplan, and Brian Morewitz also executive produce.

The post ‘Watson’ with Morris Chestnut Earns a Season 2 Order appeared first on ShowbizJunkies.


Post a Comment

0 Comments